FDA Grants Accelerated Approval to Tisotumab Vedotin-tftv for Cervical Cancer

On September 20, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tisotumab vedotin-tftv for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. 

Read the FDA announcement.

Read Seagen and Genmab's announcement.

Posted 9/21/2021